Canada:
Alexion Files For Leave To Appeal To Supreme Court Of Canada In Case Challenging Constitutionality Of Pmprb Remedial Powers
05 April 2018
Smart & Biggar
To print this article, all you need is to be registered or login on Mondaq.com.
On February 5, 2018, Alexion Pharmaceuticals filed an
application for leave to appeal a decision of the Federal Court of
Appeal (FCA) dismissing its challenge to the constitutionality of
certain of the Patented Medicine Prices Review Board (PMPRB)
provisions of the Patent Act: SCC Case No. 37949. The FCA decision,
Alexion Pharmaceuticals Inc v Canada (Attorney General),
2017 FCA 241, was previously reported
here
The preceding is intended as a timely update on Canadian
intellectual property and technology law. The content is
informational only and does not constitute legal or professional
advice. To obtain such advice, please communicate with our offices
directly.
POPULAR ARTICLES ON: Intellectual Property from Canada
Moral Right To Authorship Tied To Copyright
Oyen Wiggs Green & Mutala LLP
The Federal Court of Appeal has upheld a finding that the Royal Canadian Legion did not infringe an author's moral rights by selling poppy patterned...
Case Review 2023: Patent Motions
Seastone IP
In 2023, the Federal Court of Canada released more patent motion decisions than motion decisions in all other IP rights combined...